Literature DB >> 21060024

Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.

Christoph Schuhmacher1, Stephan Gretschel, Florian Lordick, Peter Reichardt, Werner Hohenberger, Claus F Eisenberger, Cornelie Haag, Murielle E Mauer, Baktiar Hasan, John Welch, Katja Ott, Arnulf Hoelscher, Paul M Schneider, Wolf Bechstein, Hans Wilke, Manfred P Lutz, Bernard Nordlinger, Eric Van Cutsem, Jörg R Siewert, Peter M Schlag.   

Abstract

PURPOSE: Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive postoperative chemotherapy. We examined the value of purely preoperative chemotherapy in a phase III trial with strict preoperative staging and surgical resection guidelines. PATIENTS AND METHODS: Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to preoperative chemotherapy followed by surgery or to surgery alone. To detect with 80% power an improvement in median survival from 17 months with surgery alone to 24 months with neoadjuvant, 282 events were required.
RESULTS: This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. The International Union Against Cancer R0 resection rate was 81.9% after neoadjuvant chemotherapy as compared with 66.7% with surgery alone (P = .036). The surgery-only group had more lymph node metastases than the neoadjuvant group (76.5% v 61.4%; P = .018). Postoperative complications were more frequent in the neoadjuvant arm (27.1% v 16.2%; P = .09). After a median follow-up of 4.4 years and 67 deaths, a survival benefit could not be shown (hazard ratio, 0.84; 95% CI, 0.52 to 1.35; P = .466).
CONCLUSION: This trial showed a significantly increased R0 resection rate but failed to demonstrate a survival benefit. Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21060024      PMCID: PMC3020693          DOI: 10.1200/JCO.2009.26.6114

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  17 in total

1.  Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.

Authors:  H Wilke; M Korn; U Vanhöfer; U Fink; M Stahl; P Preusser; C Köhne; U Klassen; A Harstrick; H J Schmoll; S Seeber
Journal:  J Infus Chemother       Date:  1996

Review 2.  Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.

Authors:  Xavier Paoletti; Koji Oba; Tomasz Burzykowski; Stefan Michiels; Yasuo Ohashi; Jean-Pierre Pignon; Philippe Rougier; Junichi Sakamoto; Daniel Sargent; Mitsuru Sasako; Eric Van Cutsem; Marc Buyse
Journal:  JAMA       Date:  2010-05-05       Impact factor: 56.272

3.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

Review 4.  Cancer of the esophagogastric junction.

Authors:  H J Stein; M Feith; J R Siewert
Journal:  Surg Oncol       Date:  2000-07       Impact factor: 3.279

5.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

6.  Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate.

Authors:  Markus Menges; Carsten Schmidt; Werner Lindemann; Karsten Ridwelski; Werner Pueschel; Bernhard Jüngling; Gernot Feifel; Martin Schilling; Andreas Stallmach; Martin Zeitz
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-27       Impact factor: 4.553

7.  Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection.

Authors:  U Fink; C Schuhmacher; H J Stein; R Busch; H Feussner; H J Dittler; A Helmberger; K Böttcher; J R Siewert
Journal:  Br J Surg       Date:  1995-09       Impact factor: 6.939

8.  Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Authors:  Ian Chau; Andy R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992.

Authors:  J D Roder; K Böttcher; J R Siewert; R Busch; P Hermanek; H J Meyer
Journal:  Cancer       Date:  1993-10-01       Impact factor: 6.860

10.  Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.

Authors:  Katja Ott; Andreas Sendler; Karen Becker; Hans-Joachim Dittler; Hermann Helmberger; Raimonde Busch; Christian Kollmannsberger; J Rüdiger Siewert; Ulrich Fink
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

View more
  230 in total

Review 1.  Neoadjuvant therapy for gastric cancer: current evidence and future directions.

Authors:  Andrew D Newton; Jashodeep Datta; Arturo Loaiza-Bonilla; Giorgos C Karakousis; Robert E Roses
Journal:  J Gastrointest Oncol       Date:  2015-10

2.  Staging laparoscopy improves treatment decision-making for advanced gastric cancer.

Authors:  Yan-Feng Hu; Zhen-Wei Deng; Hao Liu; Ting-Yu Mou; Tao Chen; Xin Lu; Da Wang; Jiang Yu; Guo-Xin Li
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

3.  Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis.

Authors:  Ulrike Heger; Franz Bader; Florian Lordick; Maria Burian; Rupert Langer; Martin Dobritz; Susanne Blank; Thomas Bruckner; Karen Becker; Ken Herrmann; Jörg-Rüdiger Siewert; Katja Ott
Journal:  Gastric Cancer       Date:  2013-09-01       Impact factor: 7.370

Review 4.  Treatment of gastric cancer.

Authors:  Michele Orditura; Gennaro Galizia; Vincenzo Sforza; Valentina Gambardella; Alessio Fabozzi; Maria Maddalena Laterza; Francesca Andreozzi; Jole Ventriglia; Beatrice Savastano; Andrea Mabilia; Eva Lieto; Fortunato Ciardiello; Ferdinando De Vita
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

5.  Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014.

Authors:  Naruhiko Ikoma; Janice N Cormier; Barry Feig; Xianglin L Du; Jose-Miguel Yamal; Wayne Hofstetter; Prajnan Das; Jaffer A Ajani; Christina L Roland; Keith Fournier; Richard Royal; Paul Mansfield; Brian D Badgwell
Journal:  Cancer       Date:  2018-02-02       Impact factor: 6.860

6.  Comprehensive Analysis of the Neutrophil-to-Lymphocyte Ratio for Preoperative Prognostic Prediction Nomogram in Gastric Cancer.

Authors:  Jong-Ho Choi; Yun-Suhk Suh; Yunhee Choi; Jiyeon Han; Tae Han Kim; Shin-Hoo Park; Seong-Ho Kong; Hyuk-Joon Lee; Han-Kwang Yang
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

Review 7.  [Surgical treatment of gastric carcinoma. German multicenter observational studies].

Authors:  K Ridwelski; I Gastinger; H Ptok; F Meyer; H Dralle; H Lippert
Journal:  Chirurg       Date:  2013-01       Impact factor: 0.955

8.  Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.

Authors:  Jian Ang; Liang Hu; Pin-Tong Huang; Jin-Xiu Wu; Ling-Na Huang; Chun-Hui Cao; Yi-Xiong Zheng; Li Chen
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

9.  Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.

Authors:  Lei Ge; Hai-Jiang Wang; Dong Yin; Cheng Lei; Jin-Feng Zhu; Xiao-Hui Cai; Guo-Qing Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

10.  Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study.

Authors:  Yongjia Yan; Annie Yang; Li Lu; Zhicheng Zhao; Chuan Li; Weidong Li; Joseph Chao; Tong Liu; Yuman Fong; Weihua Fu; Yanghee Woo
Journal:  Ann Surg Oncol       Date:  2020-08-29       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.